Sökning: WFRF:(Aigner Clemens) > Potential subtype-s...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 03397naa a2200349 4500 | |
001 | oai:lup.lub.lu.se:128947c3-7e30-4c39-807f-778fbcd79cfa | |
003 | SwePub | |
008 | 240131s2024 | |||||||||||000 ||eng| | |
024 | 7 | a https://lup.lub.lu.se/record/128947c3-7e30-4c39-807f-778fbcd79cfa2 URI |
024 | 7 | a https://doi.org/10.1097/CCO.00000000000010052 DOI |
040 | a (SwePub)lu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a for2 swepub-publicationtype |
072 | 7 | a ref2 swepub-contenttype |
100 | 1 | a Horvath, Lillau National Korányi Institute for Tuberculosis and Pulmonology, Hungary4 aut |
245 | 1 0 | a Potential subtype-specific therapeutic approaches in small cell lung cancer |
264 | 1 | c 2024 |
300 | a 6 s. | |
520 | a PURPOSE OF REVIEW: Small cell lung cancer (SCLC) remains one of the most aggressive thoracic malignancies with an especially dismal prognosis. While the detection of various targetable driver mutations and immune checkpoints have revolutionized the treatment of non-small cell lung cancer (NSCLC), there has been only modest therapeutic innovation over the past decades in SCLC. In this review, we aim to provide a brief summary on the clinical relevance of recent research findings, which could soon pave the way towards a more personalized and targeted management of SCLC patients. RECENT FINDINGS: Substantial research on the biological and molecular heterogeneity of SCLC has been conducted in the last years. Recent results from comprehensive profiling studies have shown that unique major SCLC subtypes can be distinguished based on the relative expression of key transcription regulators (ASCL1, NEUROD1, POU2F3) or distinct inflammatory features. Understanding the differing molecular characteristics of these distinct subtypes has resulted in the identification of specific therapeutic vulnerabilities. SUMMARY: The recently introduced molecular SCLC subtype classification represents a substantial progress towards a personalized and more efficacious approach in SCLC. The consequences of this paradigm shift provide hope for improved patient care and clinical outcomes in this exceptionally lethal thoracic malignancy. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
700 | 1 | a Lang, Christianu Medical University of Vienna4 aut |
700 | 1 | a Boettiger, Kristiina4 aut |
700 | 1 | a Aigner, Clemens4 aut |
700 | 1 | a Dome, Balazsu Lund University,Lunds universitet,Klinisk kemi, Malmö,Forskargrupper vid Lunds universitet,Clinical Chemistry, Malmö,Lund University Research Groups,Semmelweis University,National Korányi Institute for Tuberculosis and Pulmonology, Hungary4 aut0 (Swepub:lu)ba1464do |
700 | 1 | a Megyesfalvi, Zsoltu National Korányi Institute for Tuberculosis and Pulmonology, Hungary,National Institute of Oncology, Budapest4 aut |
710 | 2 | a National Korányi Institute for Tuberculosis and Pulmonology, Hungaryb Medical University of Vienna4 org |
773 | 0 | t Current Opinion in Oncologyg 36:1, s. 51-56q 36:1<51-56x 1040-8746 |
856 | 4 | u http://dx.doi.org/10.1097/CCO.0000000000001005y FULLTEXT |
856 | 4 8 | u https://lup.lub.lu.se/record/128947c3-7e30-4c39-807f-778fbcd79cfa |
856 | 4 8 | u https://doi.org/10.1097/CCO.0000000000001005 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy